Jelmyto a “paradigm shift” in treating upper tract urothelial carcinoma

An exclusive Urology Times survey measured US-based urologists’ uptake, access to, and indications for utilizing prostate-specific membrane antigen-targeting agents.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

Laura Bukavina, MD, MPH, highlights a BCAN Think Tank session on real-world applications of microbiome in bladder cancer.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

Suzanne Merrill, MD, recaps the BCAN 2023 Think Tank session she co-chaired that covered prehabilitation programs, urinary diversion management, and other focal areas aimed at enhancing the quality of bladder cancer care in the community.

In this interview, Scott Tagawa MD, highlights a session from the BCAN 2023 Think Tank exploring the latest developments in the treatment of patients with advanced urothelial carcinoma.